News and Trends 19 May 2023 Swedish company develops first effective treatment for hypothyroidism Prolevi Bio has developed a technology intended to help the 10 to 20% of people who don’t respond to current treatments for underactive thyroid glands. The company has developed a modified release thyroid hormone tablet formulation, mimicking the natural hormone release cycles. In addition, the treatment will be tailored according to each patient’s needs using […] May 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 Pathalys Pharma brings in $150M for SHPT trials Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) have announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Therapeutics is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth. Pathalys […] January 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Viridian reports positive news from ongoing trial for patients with Thyroid Eye Disease Patients with active thyroid eye disease (TED) could benefit from rapid and significant improvements after positive data emerged from a clinical trial. Viridian Therapeutics made the announcement yesterday (August 15) that the 10mg/kg cohort in its ongoing phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody TED – an autoimmune disease where the body’s own immune […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Sling Therapeutics emerges with $35M to tackle thyroid eye disease Michigan-based biopharma company Sling Therapeutics, Inc. has launched, with $35 million in series A financing led by TPG’s The Rise Fund. The company is focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The funds support a phase 2b clinical trial evaluating its investigational drug, linsitinib. “We […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email